stockrow
Friday 6 November 2026
Export PHVS’s income statement to Excel — free account
Pharvaris N.V.
PHVS Healthcare Biotechnology
- EPS
- +13.8%
- Free cash flow
- −17.3%
- Total debt
- +4.31%
Quarter to June 2026, against a year earlier
34.75
2.22
+6.82%
Follow PHVS
Alert me
Pharvaris N.V. (PHVS) Operating cash flow
Pharvaris N.V.'s operating cash flow for fiscal 2025 was −$155.1M, compared with −$130.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$178.0M. Over the past ten years it has ranged from −$155.1M (fiscal 2025) to −$4.6M (fiscal 2018) — the current reading is the lowest in ten years. Operating cash flow has fallen for 7 consecutive fiscal years. Pharvaris N.V. ranks 533rd of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$155.1M | — |
| FY2024 | −$130.0M | — |
| FY2023 | −$100.7M | — |
| FY2022 | −$70.8M | — |
| FY2021 | −$52.8M | — |
| FY2020 | −$24.6M | — |
| FY2019 | −$7.5M | — |
| FY2018 | −$4.6M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | −$43.6M | — |
| Mar 2026 | −$57.1M | — |
| Dec 2025 | −$39.2M | — |
| Sep 2025 | −$38.2M | — |
| 19 more quarters | Free account |
Against its own ten years
Low −$155.1M
High −$4.6M
Ten-year median
−$61.8M
Current reading's percentile
13
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| ADMA ADMA Biologics Inc compare | $140.8M |
| VCEL Vericel Corporation compare | $65.3M |
| PVLA Palvella Therapeutics, Inc. compare | −$36.5M |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$150.5M |
| PHVS Pharvaris N.V. | −$178.0M |
| IMNM Immunome, Inc. compare | −$208.8M |
| CLDX Celldex Therapeutics, Inc. compare | −$235.6M |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$310.5M |
| BHVN Biohaven Ltd. compare | −$472.5M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item